Machold et al., 1992 - Google Patents
Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study.Machold et al., 1992
View PDF- Document ID
- 1690039128707557626
- Author
- Machold K
- Neumann K
- Smolen J
- Publication year
- Publication venue
- Annals of the rheumatic diseases
External Links
Snippet
Interferon gamma (IFN gamma) has been advocated in open studies as a beneficial remission inducing drug for the treatment of rheumatoid arthritis (RA). The work reported here was designed to assess the therapeutic potential of IFN gamma in the treatment of RA …
- 239000000902 placebo 0 title abstract description 46
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Machold et al. | Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. | |
| Sakkas et al. | T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis | |
| Lu et al. | Identification of the osteoprotegerin/receptor activator of nuclear factor‐kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis | |
| Debandt et al. | Anti-TNF-α-induced systemic lupus syndrome | |
| Lindberg et al. | Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases | |
| Catrina et al. | Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis | |
| Yanni et al. | Synovial tissue macrophages and joint erosion in rheumatoid arthritis. | |
| Booth et al. | Safety and efficacy of TNFα blockade in relapsing vasculitis | |
| Alstergren et al. | Interleukin-1β in synovial fluid from the arthritic temporomandibular joint and its relation to pain, mobility, and anterior open bite | |
| Barrera et al. | Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis | |
| KAUFMAN et al. | L-Tryptophan-associated eosinophilic perimyositis, neuritis, and fasciitis: a clinicopathologic and laboratory study of 25 patients | |
| Veys et al. | A randomized, double‐blind study comparing twenty‐four‐week treatment with recombinant interferon‐γ versus placebo in the treatment of rheumatoid arthritis | |
| Schumacher et al. | Articular manifestations of polymyositis and dermatomyositis | |
| Perkins et al. | Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti‐tumor necrosis factor α monoclonal antibody (cA2) | |
| Huang et al. | Exposure to receptor-activator of NFκB ligand renders pre-osteoclasts resistant to IFN-γ by inducing terminal differentiation | |
| Ohta et al. | Paraproteinemia in patients with scleredema: clinical findings and serum effects on skin fibroblasts in vitro | |
| Furmanski et al. | Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor | |
| Trieger et al. | The effect of arthrocentesis of the temporomandibular joint in patients with rheumatoid arthritis | |
| Cho et al. | Tumor necrosis factor α activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro‐resorptive factors | |
| DK1720893T3 (en) | COMPOSITIONS AND PROCEDURES FOR THE SYSTEMIC TREATMENT OF ARTHRITIS | |
| German Lymphokine Study Group et al. | Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis | |
| JPH01110633A (en) | Liver cell stimulant factor | |
| Conn et al. | Raised serum immunoglobulin E in Wegener's granulomatosis. | |
| Fudman et al. | Scleromyxedema with systemic involvement mimics rheumatic diseases | |
| Punzi et al. | Synovial fluid levels of proinflammatory interleukins and their inter-relationships in elderly vs younger onset rheumatoid arthritis |